Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity

Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

(2015) Anders Österborg et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

(2015) D. M. Benson et al.   CLINICAL CANCER RESEARCH

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

(2015) C. Moreno et al.   HAEMATOLOGICA

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

(2015) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

(2015) Susann Szmania et al.   JOURNAL OF IMMUNOTHERAPY

Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

(2015) Naoyuki Sakamoto et al.   Journal of Translational Medicine

Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*

(2015) Matt E. Kalaycio et al.   LEUKEMIA & LYMPHOMA

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection

(2015) W. Deng et al.   SCIENCE

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

(2015) C. Moreno et al.   HAEMATOLOGICA

Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress

(2015) Meriem Hasmim et al.   Frontiers in Immunology

Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer

(2015) Jeannette Cany et al.   OncoImmunology

Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1

(2015) Vanessa Kruse et al.   PLoS One

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation

(2014) N. N. Shah et al.   BLOOD

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

(2014) G. Cartron et al.   BLOOD

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

(2014) M. K. Gleason et al.   BLOOD

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

(2014) V. Bachanova et al.   BLOOD

Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial

(2014) Michelle Furtado et al.   BRITISH JOURNAL OF HAEMATOLOGY

NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma

(2014) Cheng Sun et al.   Cellular & Molecular Immunology

Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

(2014) Y. Mao et al.   CLINICAL CANCER RESEARCH

Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis

(2014) Ole Helm et al.   INTERNATIONAL JOURNAL OF CANCER

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis

(2014) Antonino Bruno et al.   JNCI-Journal of the National Cancer Institute

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

(2014) Kristen N. Ganjoo et al.   LEUKEMIA & LYMPHOMA

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia

(2014) Carolyn M Cheney et al.   mAbs

Frozen Cord Blood Hematopoietic Stem Cells Differentiate into Higher Numbers of Functional Natural Killer Cells In Vitro than Mobilized Hematopoietic Stem Cells or Freshly Isolated Cord Blood Hematopoietic Stem Cells

(2014) Martha Luevano et al.   PLoS One

IL-12 Directs Further Maturation of Ex Vivo Differentiated NK Cells with Improved Therapeutic Potential

(2014) Dorit Lehmann et al.   PLoS One

Human natural killer cell development in secondary lymphoid tissues

(2014) Aharon G. Freud et al.   SEMINARS IN IMMUNOLOGY

Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept

(2014) Guido Giordano et al.   Gastroenterology Research and Practice

The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment

(2014) Delia Nelson et al.   Journal of Immunology Research

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

(2013) J. N. Kochenderfer et al.   BLOOD

Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression

(2013) L Wyler et al.   BRITISH JOURNAL OF CANCER

A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma

(2013) Bertrand Coiffier et al.   BRITISH JOURNAL OF HAEMATOLOGY

Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

(2013) Fumitaka Arihara et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor- 

(2013) G. Kohanbash et al.   CANCER RESEARCH

Melanoma-Educated CD14 + Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2–Dependent Mechanisms

(2013) Yumeng Mao et al.   CANCER RESEARCH

Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials

(2013) H. Fang et al.   CANCER RESEARCH

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

(2013) A. Wiernik et al.   CLINICAL CANCER RESEARCH

Treatment of patients with advanced cancer with the natural killer cell line NK-92

(2013) Torsten Tonn et al.   CYTOTHERAPY

A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia

(2013) Yoshiaki Ogawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

(2013) Michinori Ogura et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis

(2013) Gang Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Franck Andre Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-2–dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells

(2013) Georg Gasteiger et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells

(2013) Isabel Jungkunz-Stier et al.   LEUKEMIA & LYMPHOMA

GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present

(2013) Delila J. Kern et al.   LEUKEMIA & LYMPHOMA

The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential

(2013) Béatrice Clémenceau et al.   mAbs

Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy

(2013) J Shortt et al.   ONCOGENE

Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice

(2013) Jeannette Cany et al.   PLoS One

Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells

(2013) Subhashis Sarkar et al.   PLoS One

Reduction of the CD16−CD56bright NK Cell Subset Precedes NK Cell Dysfunction in Prostate Cancer

(2013) Kyo Chul Koo et al.   PLoS One

Antibody Therapeutics in Cancer

(2013) M. X. Sliwkowski et al.   SCIENCE

Targeting Angiogenesis and the Tumor Microenvironment

(2013) Jennifer Samples et al.   Surgical Oncology Clinics of North America

Activating natural cytotoxicity receptors of natural killer cells in cancer and infection

(2013) Joachim Koch et al.   TRENDS IN IMMUNOLOGY

Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy

(2013) David A. Knorr et al.   Stem Cells Translational Medicine

Therapeutic applications: natural killer cells in the clinic

(2013) J. S. Miller   Hematology-American Society of Hematology Education Program

Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells

(2013) Ashley Mentlik James et al.   Frontiers in Immunology

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

(2012) M. S. Czuczman et al.   BLOOD

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

(2012) G. Salles et al.   BLOOD

Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity

(2012) G. Pietra et al.   CANCER RESEARCH

Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma

(2012) Michinori Ogura et al.   CANCER SCIENCE

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

(2012) Andres Forero-Torres et al.   CLINICAL CANCER RESEARCH

Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?

(2012) L.H.A.M. de Wilt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy

(2012) Tolga Sutlu et al.   HUMAN GENE THERAPY

Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy

(2012) Caroline Veuillen et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

(2012) M. K. Gleason et al.   MOLECULAR CANCER THERAPEUTICS

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

(2012) Cecele J. Denman et al.   PLoS One

Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products

(2012) Robert Skeate et al.   TRANSFUSION

The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages

(2012) Daria Capece et al.   Biomed Research International

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

(2011) W. G. Wierda et al.   BLOOD

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

(2011) A. Curti et al.   BLOOD

Identification of the earliest NK-cell precursor in the mouse BM

(2011) S. Carotta et al.   BLOOD

H2O2 production within tumor microenvironment inversely correlated with infiltration of CD56dim NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction

(2011) Shinichirou Izawa et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: A potential mechanism of immune escape

(2011) Cheng Chen et al.   CANCER LETTERS

Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression

(2011) M. R. Parkhurst et al.   CLINICAL CANCER RESEARCH

Ex vivo expansion of natural killer cells: a question of function

(2011) Tolga Sutlu et al.   CYTOTHERAPY

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Endostatin- and interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinoma

(2011) Flávia Gomes de Góes Rocha et al.   JOURNAL OF GENE MEDICINE

Natural Killer Cell Responses to Viral Infection

(2011) Joshua D. Brandstadter et al.   Journal of Innate Immunity

Tumor-Associated Macrophages Recruit CCR6+ Regulatory T Cells and Promote the Development of Colorectal Cancer via Enhancing CCL20 Production in Mice

(2011) Jinlin Liu et al.   PLoS One

Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process

(2011) Jan Spanholtz et al.   PLoS One

IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study

(2011) Claudia Brehm et al.   PLoS One

Infusion of allogeneic natural killer cells in a patient with acute myeloid leukemia in relapse after haploidentical hematopoietic stem cell transplantation

(2011) Stéphanie Nguyen et al.   TRANSFUSION

Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells

(2011) Srinivas S. Somanchi et al.   Jove-Journal of Visualized Experiments

Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation

(2010) David A. Rizzieri et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans

(2010) Michael C. Jensen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma

(2010) Y. Lin et al.   BLOOD

Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome

(2010) Michael J. Campbell et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer

(2010) Eleni G. Iliopoulou et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign

(2010) Isabel Poschke et al.   CANCER RESEARCH

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients

(2010) Uwe Siegler et al.   CYTOTHERAPY

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor

(2010) Tolga Sutlu et al.   CYTOTHERAPY

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

(2010) Melissa A. Geller et al.   CYTOTHERAPY

NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma

(2010) M. Watanabe et al.   DISEASES OF THE ESOPHAGUS

NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia

(2010) Jeffrey E. Rubnitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells

(2010) M. G. Lechner et al.   JOURNAL OF IMMUNOLOGY

IL-2−driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16− Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion

(2010) Sabine Huenecke et al.   JOURNAL OF IMMUNOTHERAPY

Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That Is Reversed With IL-2 Exvivo Expansion

(2010) Dongxia Xing et al.   JOURNAL OF IMMUNOTHERAPY

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

(2010) M Le Garff-Tavernier et al.   LEUKEMIA

Differential effects of IL-2 and IL-21 on expansion of the CD4+CD25+Foxp3+T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia

(2010) Aruna Gowda et al.   mAbs

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Different Patterns of Evolution in the Centromeric and Telomeric Regions of Group A and B Haplotypes of the Human Killer Cell Ig-Like Receptor Locus

(2010) Chul-Woo Pyo et al.   PLoS One

Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity

(2009) P. S. Woll et al.   BLOOD

Education of human natural killer cells by activating killer cell immunoglobulin-like receptors

(2009) C. Fauriat et al.   BLOOD

Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study

(2009) S R Yoon et al.   BONE MARROW TRANSPLANTATION

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

(2009) H. Fujisaki et al.   CANCER RESEARCH

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

(2009) Maria Berg et al.   CYTOTHERAPY

Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma

(2009) Frank A. Sinicrope et al.   GASTROENTEROLOGY

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor

(2009) Bastian Hoechst et al.   HEPATOLOGY

Safety analysis ofex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study

(2009) Lisbeth Barkholt et al.   Immunotherapy

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

(2009) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy – a case report

(2009) Valeria Milani et al.   Journal of Translational Medicine

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

(2008) E. Alici et al.   BLOOD

Human Leukocyte Antigen-G and Cancer Immunoediting

(2008) M. Urosevic et al.   CANCER RESEARCH

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients

(2008) Lun Cai et al.   CLINICAL IMMUNOLOGY

Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL

(2008) W. Jiang et al.   CYTOTHERAPY

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY